Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLITone
- Development stage
- Phase 3
- Lead developer
- ALK Abelló
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
**SLITone** is an ALK-Abelló branded, allergen-specific sublingual immunotherapy product line delivered as once-daily allergen-extract drops in single-dose containers. It is not one fixed molecular entity: the prescribed extract may contain house dust mite allergens, grass pollen, olive pollen, or other allergen preparations and mixtures selected for the patient's clinically relevant sensitizations. Repeated sublingual exposure is intended to induce allergen-specific immune tolerance, reducing allergic symptoms and use of rescue medication. Published studies and registered trials include SLITone Dermatophagoides mixes for house dust mite-associated asthma and allergic rhinitis, as well as house dust mite SLITone in atopic dermatitis. ([ctv.veeva.com](https://ctv.veeva.com/study/efficacy-of-slitone-in-house-dust-mite-allergic-patients))
- Brand names
- SLITone
- Other names
- SLITOne
02
Targets
Cypress pollen allergensDer f (Dermatophagoides farinae allergens)Phleum pratense allergensOlive pollen allergensParietaria judaica pollen allergen
Beyond the preview
Go deeper on SLITone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLITone.